In a move that caught both Wall Street and the wider healthcare sector by surprise, Warren Buffett’s Berkshire Hathaway disclosed a significant new investment of more than 5 million shares in leading U.S. insurer UnitedHealth Group (UNH), valued at approximately $1.6 billion at the close of the previous quarter. The revelation, made through Berkshire’s quarterly 13F filing with regulators, provided a rare vote of confidence in a company that has recently faced high-profile setbacks and sector-wide uncertainty.

UnitedHealth, the nation’s largest private health insurer by market capitalization, has struggled in 2025 due to a host of issues including a Department of Justice investigation into its Medicare billing practices, sharp stock price declines, and significant executive turnover. The company’s shares, which had fallen nearly 50% year-to-date by mid-August, spiked more than 6% in after-hours trading after news broke of Buffett’s sizable new position.

Berkshire’s Portfolio Shuffle: Value Investing in Action

The addition of UnitedHealth places it as the 18th largest holding in Berkshire Hathaway’s equity portfolio—which is valued at more than $300 billion—behind such giants as Amazon and Constellation Brands, according to VerityData. While Warren Buffett’s legendary investment acumen draws much attention, industry analysts note that the purchase may have been executed by one of his trusted investment managers, Todd Combs or Ted Weschler. This echoes previous major investments, such as Berkshire’s 2019 entry into Amazon, which were attributed to Buffett’s lieutenants.

Berkshire’s most recent disclosures also revealed several fresh investments in companies tied to housing and heavy industry, including top homebuilders Lennar (LEN) and D.R. Horton (DHI), as well as steel producer Nucor (NUE). These selective moves into cyclical sectors underscore the conglomerate’s typical value-oriented, contrarian approach—investing in challenged sectors at moments of pessimism when bargains are likeliest to emerge.

UnitedHealth: Troubles and Opportunities Amid Healthcare Turbulence

UnitedHealth’s prominence in the U.S. healthcare system is matched by its recent struggles. Earlier in 2025, the insurer pulled its annual earnings guidance as it continued grappling with legal and operational challenges. In May, longtime CEO Andrew Witty resigned in the face of intense regulatory scrutiny and shareholder pressure, further unsettling markets and pushing UnitedHealth’s share price to decade-lows. In July, a revised 2025 outlook disappointed Wall Street, fueling further sell-offs.

Yet, some investors—including Berkshire as well as notable hedge fund managers like Michael Burry and David Tepper (Appaloosa Management)—appear to be taking the long view. UnitedHealth’s stock now trades at a price-to-earnings (P/E) ratio below 12—one of its lowest valuations in more than ten years—potentially offering significant upside if the company can resolve its legal troubles and stabilize its business.

Market analysts suggest that Berkshire’s buy may signal a turnaround opportunity. Healthcare spending continues to rise nationwide, and UnitedHealth remains a dominant force in Medicare Advantage, Medicaid, and employer-sponsored health plans. Despite short-term headwinds, its expansive reach and data-driven approach could help it rebound, especially if federal investigations resolve in the company’s favor. Analysts at major firms such as Morgan Stanley and J.P. Morgan have recently noted that while risk remains elevated, current share prices may significantly underestimate UnitedHealth’s long-term cash flow potential.

Strategic Reshuffling: Beyond Healthcare

The UnitedHealth bet comes amid a broader realignment within Berkshire Hathaway’s mammoth portfolio. The conglomerate took new or expanded stakes in homebuilders Lennar and D.R. Horton—both companies that benefited from the post-pandemic housing boom and remain among the largest U.S. home construction firms by market cap, despite signs of a slowing real estate market as mortgage rates hover near multi-decade highs.

In the industrial space, Berkshire added Nucor, the largest U.S. steelmaker, leading to an 8% pop in Nucor’s shares—reflecting the market’s belief in Buffett’s ability to spot value. Lennar and D.R. Horton also rose about 3% each in after-hours trading.

At the same time, Berkshire reduced its exposure in two of its cornerstone holdings: Apple (AAPL)—still the conglomerate’s largest single position—and Bank of America (BAC). The Apple cut amounted to a roughly 7% trim, possibly reflecting shifting risk assessments or an effort to free capital for new opportunities.

Buffett Prepares for Transition: What’s Next for Berkshire?

As Warren Buffett approaches his 95th birthday, 2025 marks a pivotal year for the company he has grown for decades. Buffett has announced plans to step down as CEO at year’s end, passing day-to-day leadership to Greg Abel, current Vice Chairman of the company’s non-insurance operations. However, Buffett will retain his role as Chairman of the Board, preserving his influence over Berkshire’s culture and direction.

The company has not designated an official successor for its portfolio management duties. Still, Buffett has suggested that Greg Abel will have the authority for all capital allocation decisions—an indication of Berkshire’s focus on maintaining its decentralized, disciplined investment philosophy.

The latest buys and sells are being closely scrutinized by investors for insights into how Berkshire’s next era might unfold. Whether the UnitedHealth move ultimately proves prescient will depend on developments in both healthcare policy and the company’s ability to restore investor confidence amid a period of turbulence.

Market Impact and Future Outlook

With its latest 13F filing, Berkshire Hathaway has once again signaled its willingness to cut against prevailing sentiment and take calculated risks on embattled, undervalued sectors. Its new stakes in UnitedHealth, homebuilders, and heavy industry come alongside tactical reductions in dominant tech and banking positions, refocusing the portfolio on long-term value and potential recovery plays.

As 2025 progresses, investors and market watchers alike will be watching Berkshire’s evolving portfolio for further signals of how America’s most-watched investor sees the road ahead.